Profit outpacing revenue
Profit grew 148.4% while revenue grew 22.7%, so the company kept more of each rupee of revenue as profit.
Importance 72 / 95 · growth
The strongest observations the engine found, ranked. Every line is generated from the filed numbers by a fixed rule — no opinion, no estimate.
Profit grew 148.4% while revenue grew 22.7%, so the company kept more of each rupee of revenue as profit.
Importance 72 / 95 · growth
Over 5 years the stock returned 36.6% a year while profit shrank 2.0% a year.
Importance 64 / 95 · business vs stock
Profit has swung sharply over 7 years (from ₹94 to ₹984) — one year is a weak guide to the earnings power.
Importance 58 / 95 · growth
Classified by the exchange under Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals.
Peer set used on this page: 12 pharmaceuticals.
Revenue grew 15.4% a year over 7 years, from ₹2,236 cr in FY2019 to ₹6,089 cr in FY2026. Net profit grew 34.1% a year over the same period.
Profit grew 148.4% while revenue grew 22.7%, so the company kept more of each rupee of revenue as profit.
Rule PROFIT_FASTER_THAN_REVENUE
Profit has swung sharply over 7 years (from ₹94 to ₹984) — one year is a weak guide to the earnings power.
Over 7 years profit compounded at 37.9% a year while revenue compounded at 16.8% a year — though FY2021 saw a one-off step-change of 285% (a merger, restructuring or a recovery off a low base), so the compounding is uneven.
Revenue compounded at 16.8% a year over 7 years (₹2,292 → ₹6,813) — though FY2021 saw a one-off step-change of 70% (a merger, restructuring or a recovery off a low base), so the compounding is uneven.
Net profit rose 148.4% to ₹890 — but FY2025 was a depressed ₹358 (vs a ~₹524 historical norm), so this is a recovery. Profit has compounded 37.9% a year over 7 years.
Revenue grew 22.7% year on year (FY2025 → FY2026).
In Q2 FY27 (Jul–Sep 2026), revenue was ₹2,206 cr (up 33.4% on the same quarter last year) and net profit ₹436 cr (up 124%).
Quarterly results, the trailing-twelve-months snapshot, and verified corporate actions — kept separate from each other and from the annual story above. Every figure traces to a filed number; nothing here is external news or commentary.
Q2 FY27 net profit was ₹436 cr, up 124.3% from ₹194 cr a year earlier.
Rule QTR_PROFIT_GROWTH_YOY
Q2 FY27 revenue was ₹2,206 cr, up 33.4% from ₹1,653 cr in Q2 FY26 a year earlier.
Rule QTR_REVENUE_GROWTH_YOY
Q2 FY27 net profit grew 124.3% while revenue grew 33.4% vs the same quarter last year — a gap of 90.8 percentage points.
Rule QTR_PROFIT_VS_REVENUE_GROWTH
| Quarter | Revenue | YoY | Net profit | YoY | Net margin |
|---|---|---|---|---|---|
| Q3 FY25 | 1,415 | +18.4% | 93 | +298.2% | 6.6% |
| Q4 FY25 | 1,720 | +19.5% | 233 | +210.3% | 13.5% |
| Q1 FY26 | 1,570 | +31.4% | 162 | +1175.1% | 10.3% |
| Q2 FY26 | 1,653 | +35.1% | 194 | +874.9% | 11.8% |
| Q3 FY26 | 1,778 | +25.7% | 252 | +171.0% | 14.2% |
| Q4 FY26 | 1,812 | +5.3% | 282 | +21.2% | 15.6% |
| Q1 FY27 | 2,026 | +29.1% | 362 | +123.9% | 17.9% |
| Q2 FY27 | 2,206 | +33.4% | 436 | +124.3% | 19.8% |
Trailing twelve months to 30 Sept 2026 · sum of the last 4 contiguous quarters
EBITDA margin was 24.9% in FY2026, against 16.4% in FY2019. ROE was 15.1% and ROCE 16.1% in FY2026.
EBITDA margin improved from 20.4% to 26.9% of revenue.
Rule MARGIN_EXPANDED_YOY
ROE rose from 8.2% to 17.7% — but FY2025 was a depressed year, so this is a rebound rather than a step-up.
EBITDA margin has ranged from 15.9% to 32.7% over 7 years and sits at 26.9% now.
Debt-to-equity was 0.38x in FY2026, against 0.58x in FY2019; interest coverage 7.95x. Operating cash flow was 1.87x net profit.
Operating cash flow has matched or exceeded reported profit in 5 of the last 6 profit-making years (latest 1.82×).
Rule CFO_CONSISTENTLY_EXCEEDS_PAT
Net worth compounded at 19.5% a year over 7 years (₹1,558 → ₹5,431) — though FY2021 saw a one-off step-change of 47% (a merger, restructuring or a recovery off a low base), so the compounding is uneven.
Free cash flow has been positive in 5 of the last 6 years.
Within its 12-company Pharmaceuticals peer group, it ranks 3 of 12 on return on equity and 8 of 12 on EBITDA margin. Its P/E of 93.0 compares with a peer median of 45.3.
Ranked against 12 pharmaceuticals (FY2026, consolidated).
LAURUSLABS · 3rd of 12 · set median 14.8%
LAURUSLABS · 8th of 12 · set median 28.7%
LAURUSLABS · 3rd of 12 · set median 14.4%
LAURUSLABS · 11th of 12 · set median 45.3×
Trades at 93.00× earnings — 105% above the pharmaceuticals median of 45.29×.
Rule PE_ABOVE_PEERS
On the trailing twelve months. Last full year: P/E 139.2× · P/S 18.0× · ROE 17.7%. TTM and full-year profit and EBITDA differ by more than 15% — a one-off in a recent quarter is moving the trailing figure; weigh it against the full year.
The share price is up 132% over 1 year, up 514% over 3 years (83.1% a year) and up 376% over 5 years (36.6% a year). These are price changes excluding dividends, adjusted for splits and bonuses, to 20 Nov 2026; it is 6.3% below its 52-week high.
Over 5 years the stock returned 36.6% a year while profit shrank 2.0% a year.
Rule STOCK_RAN_AHEAD
Price-action indicators as of 2026-11-20. Secondary to the fundamentals above — included for timing context, not as a signal.
Observations the engine tagged watch or deteriorating — prompts for your own research, not conclusions.
The full statements, kept deliberately secondary. Every figure traces to a BSE Integrated Filing (inline XBRL); ratios are recomputed from the normalised facts.
| Metric | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2,236 | 2,797 | 4,769 | 4,707 | 5,773 | 4,812 | 5,217 | 6,089 |
| Total income | 2,252 | 2,803 | 4,796 | 4,729 | 5,789 | 4,860 | 5,317 | 6,167 |
| EBITDA | 368 | 576 | 1,537 | 1,307 | 1,498 | 797 | 1,045 | 1,516 |
| Profit before tax | 121 | 304 | 1,275 | 975 | 1,051 | 301 | 504 | 994 |
| Net profit | 95 | 267 | 956 | 750 | 760 | 224 | 380 | 740 |
| EPS (₹) | 8.9 | 25.0 | 17.9 | 14.0 | 14.1 | 4.2 | 7.1 | 13.7 |
| Net worth | 1,591 | 1,816 | 2,712 | 3,388 | 4,057 | 4,207 | 4,564 | 5,252 |
| Total debt | 916 | 927 | 1,260 | 1,620 | 1,681 | 2,049 | 2,325 | 1,999 |
| Operating cash flow | — | — | 694 | 823 | 882 | 659 | 540 | 1,385 |
| Free cash flow | — | — | 98 | 62 | 141 | 293 | 258 | 677 |
| Ratio | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| Growth | ||||||||
| Revenue growth YoY | — | 25.1 | 70.5 | -1.3 | 22.7 | -16.6 | 8.4 | 16.7 |
| Profit growth YoY | — | 181.1 | 258.0 | -21.5 | 1.4 | -70.6 | 70.0 | 94.7 |
| Profitability | ||||||||
| EBITDA margin % | 16.4 | 20.6 | 32.2 | 27.8 | 25.9 | 16.6 | 20.0 | 24.9 |
| Net margin % | 4.2 | 9.5 | 19.9 | 15.9 | 13.1 | 4.6 | 7.2 | 12.0 |
| Return on equity % | 6.0 | 15.7 | 42.2 | 24.6 | 20.4 | 5.4 | 8.7 | 15.1 |
| Return on capital % | 8.3 | 14.9 | 39.9 | 23.9 | 22.3 | 7.5 | 10.4 | 16.1 |
| Leverage & cash | ||||||||
| Debt to equity | 0.58 | 0.51 | 0.46 | 0.48 | 0.41 | 0.49 | 0.51 | 0.38 |
| Cash flow ÷ profit | — | — | 0.73 | 1.10 | 1.16 | 2.94 | 1.42 | 1.87 |
| Current ratio | 1.04 | 1.09 | 1.29 | 1.32 | 1.51 | 1.29 | 1.27 | 1.34 |